Semaglutide plus amylin analog effective for glycemic control, weight loss in T2DM

In a phase 2 trial involving 92 adults with type 2 diabetes and BMI ≥27 on metformin +/- an SGLT2 inhibitor, those assigned to treatment with the long-acting amylin analog cagrilintide plus semaglutide (CagriSema) had a greater mean change in A1c vs. cagrilintide alone (-0.9%) at 32 weeks, but not vs. semaglutide alone. CagriSema resulted in significantly greater weight loss than either agent alone and was well tolerated.